David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Aramark
ARMK
$15.8B
| $94M | 0.12% |
4,407,285
+2,054,354
| +87% | +$46M |
|
202
PUT
Caterpillar
CAT
$381B
| $93.3M | 0.12% |
688,400
-475,800
| -41% | -$63.2M |
|
203
Best Buy
BBY
$18.1B
| $92.8M | 0.12% |
1,306,541
+278,950
| +27% | +$17.4M |
|
204
Amdocs
DOX
$6.41B
| $92.1M | 0.12% |
1,701,617
+323,474
| +23% | +$18.2M |
|
205
Incyte
INCY
$25.9B
| $91.6M | 0.12% |
1,065,227
-216,838
| -17% | -$17.6M |
|
206
Phillips 66
PSX
$96.9B
| $91.4M | 0.12% |
960,320
+167,789
| +21% | +$15.9M |
|
|
ACIA
207
DELISTED
Acacia Communications Inc
ACIA
| $90.7M | 0.12% |
1,581,731
+1,026,380
| +185% | +$49.1M |
|
208
CALL
ExxonMobil
XOM
$679B
| $90M | 0.12% |
1,113,400
+589,400
| +112% | +$44.9M |
|
209
Textron
TXT
$14.3B
| $90M | 0.12% |
1,775,750
+975,765
| +122% | +$50.3M |
|
210
Sea Limited
SE
$72B
| $88.3M | 0.11% |
+3,755,757
| New | +$65.8M |
|
211
Nutrien
NTR
$35.9B
| $88.2M | 0.11% |
1,671,003
+50,367
| +3% | +$2.62M |
|
212
Under Armour
UAA
$2.32B
| $88.1M | 0.11% |
4,166,961
+1,297,361
| +45% | +$27.2M |
|
213
CALL
Chevron
CVX
$403B
| $88M | 0.11% |
714,400
+290,100
| +68% | +$34.3M |
|
214
CALL
JPMorgan Chase
JPM
$935B
| $87.1M | 0.11% |
860,800
+365,100
| +74% | +$37.6M |
|
215
Capital One
COF
$134B
| $85.9M | 0.11% |
1,051,617
-175,920
| -14% | -$14.3M |
|
216
CALL
Eli Lilly
LLY
$1.12T
| $85.7M | 0.11% |
660,700
+506,700
| +329% | +$61.6M |
|
|
CELG
217
CALL
DELISTED
Celgene Corp
CELG
| $85.7M | 0.11% |
908,000
-34,700
| -4% | -$3.03M |
|
218
MongoDB
MDB
$34.7B
| $85M | 0.11% |
578,185
+501,986
| +659% | +$51.5M |
|
219
Union Pacific
UNP
$183B
| $83.7M | 0.11% |
500,625
-463,805
| -48% | -$74.6M |
|
220
Cognizant
CTSH
$27.9B
| $83.6M | 0.11% |
1,153,512
+690,646
| +149% | +$48.3M |
|
221
CALL
Micron Technology
MU
$1.09T
| $83.4M | 0.11% |
2,018,200
+1,009,100
| +100% | +$39M |
|
222
CALL
Merck
MRK
$376B
| $83.2M | 0.11% |
1,048,314
-200,168
| -16% | -$15M |
|
|
SINA
223
DELISTED
Sina Corp
SINA
| $82.4M | 0.11% |
1,391,500
+207,827
| +18% | +$12.5M |
|
224
PUT
Morgan Stanley
MS
$336B
| $82M | 0.11% |
1,944,300
+350,900
| +22% | +$14.8M |
|
225
Yelp
YELP
$1.27B
| $81.8M | 0.11% |
2,371,148
+913,847
| +63% | +$33M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.